Patent Issued for Immunogenic WT-1 peptides and methods of use thereof (USPTO 11859015).

A patent has been issued for immunogenic WT-1 peptides and their methods of use, assigned to Memorial Sloan Kettering Cancer Center. The patent focuses on the development of peptides derived from the Wilms tumor protein 1 (WT1) for immunotherapy in the treatment of various cancers, including leukemia. The invention aims to overcome the limitations of current WT1-derived peptides by identifying peptides that bind to multiple HLA haplotypes, allowing for a broader range of therapeutic applications. The patent describes isolated peptides and compositions that can induce immune responses to WT1-expressing cancers and stimulate T cells for treatment. It also provides detailed information about the isolated peptides, pharmaceutical compositions, vectors, and methods of administration. This patent may be of interest to researchers and medical professionals working in the field of cancer immunotherapy. [Extracted from the article]

Copyright of Cancer Vaccine Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)